Evvy launches at-home UTI test built for faster, accurate, targeted care
Results delivered in one business day
Evvy has announced the launch of the Evvy UTI+ Test, an at-home PCR urine test designed to detect 12 uropathogens and seven antibiotic-resistance markers, with results delivered in just one business day. If eligible, users can also access same-day targeted prescription treatment based on their individual results.
The company says the new test is intended to address longstanding gaps in standard U.S. urinary tract infection (UTI) care. UTIs are the most common infection among women, yet traditional urine cultures can miss 60–70% of pathogens and often take several days to return results. According to Evvy, these limitations contribute to nearly half of patients receiving an antibiotic that may not effectively treat their infection, resulting in prolonged symptoms, repeat clinical visits, and unnecessary antibiotic exposure.
“At Evvy, we believe women deserve better than guesswork,” said Dr. Kate McLean, OBGYN and Chief Medical Officer at Evvy.
“We designed the UTI+ Test to solve a big failure of current UTI care: incomplete detection. By using PCR to identify 12 key pathogens, we can treat UTIs with accuracy and precision. The result is simple but profound – patients finally get better without the trial-and-error approach that has plagued UTI care for generations.”
Support for recurring UTIs
For the 1 in 4 women who experience recurring UTIs, Evvy can offer additional insight through their existing vaginal microbiome test.
Evvy pointed to emerging research indicating that the vaginal microbiome can influence urinary health, including acting as a reservoir for UTI-causing bacteria. In its dataset, 47% of users who reported a recent UTI had UTI-related bacteria detected through Evvy’s vaginal microbiome test.
The UTI+ Test expands Evvy’s precision women’s health platform, which now combines testing for the vaginal microbiome, UTIs, and STIs with personalized prescription care and one-to-one coaching.
The test is now available in the U.S., excluding Alaska, Hawaii, and New York, at a retail price of $248 or $218 with a subscription.
Founded in 2021, Evvy focuses on closing the gender health gap by leveraging overlooked female biomarkers, including through its metagenomic Vaginal Microbiome Test. The company reports having built the world’s largest dataset on the vaginal microbiome to date. In October it reported that it now supports 75,000 patients and 2,000 healthcare providers with its vaginal microbiome testing and care platform.